Jiangsu Hengrui Medicine Co., Ltd. (SHA:600276)

Jiangsu Hengrui Medicine Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	24,086	24,816	20,746	15,111	13,631	10,805
Trading Asset Securities	110.12	273.34	99.05	2,760	5,090	5,628
Cash & Short-Term Investments	24,196	25,089	20,845	17,871	18,721	16,433
Cash Growth	11.13%	20.36%	16.64%	-4.54%	13.93%	21.15%
Accounts Receivable	7,298	6,159	6,135	8,341	6,884	8,176
Other Receivables	40.96	66.41	438.25	562.18	658	651.15
Receivables	7,339	6,226	6,573	8,904	7,542	8,827
Inventory	2,401	2,417	2,314	2,451	2,403	1,778
Prepaid Expenses	-	239.54	226.07	507.2	431.57	410.18
Other Current Assets	2,034	1,343	1,329	1,201	1,090	602.25
Total Current Assets	35,970	35,315	31,287	30,934	30,188	28,050
Property, Plant & Equipment	7,085	6,928	6,629	6,676	6,276	4,585
Long-Term Investments	1,707	1,732	1,451	1,508	1,001	1,502
Other Intangible Assets	1,381	1,192	883.77	519.9	442.45	341.25
Long-Term Deferred Tax Assets	415.44	377.17	320.56	238.9	141.36	52.97
Long-Term Deferred Charges	4,197	4,112	2,829	2,052	569.38	197.63
Other Long-Term Assets	537.91	479.11	383.3	442.55	648.99	-
Total Assets	51,293	50,136	43,785	42,371	39,266	34,730
Accounts Payable	1,997	1,517	1,334	1,493	1,920	1,151
Accrued Expenses	5.1	941.05	578.85	97.57	165.66	130.54
Short-Term Debt	-	-	-	1,261	-	-
Current Portion of Leases	45.96	41.13	-	-	-	-
Current Income Taxes Payable	439.2	242.94	59.28	4.03	21.77	25.14
Current Unearned Revenue	162.69	159.79	198.09	187.08	219.55	358.06
Other Current Liabilities	712.8	731.36	383.42	596.13	1,074	2,107
Total Current Liabilities	3,363	3,634	2,554	3,639	3,402	3,772
Long-Term Leases	62.71	69.04	75.18	98.86	151.59	-
Long-Term Unearned Revenue	216.37	225.65	38.95	119.44	116.52	141.24
Long-Term Deferred Tax Liabilities	101.05	117.11	83.64	100.45	24.77	29.76
Total Liabilities	3,743	4,045	2,751	3,958	3,694	3,943
Common Stock	6,379	6,379	6,379	6,379	6,396	5,332
Additional Paid-In Capital	2,854	3,188	3,058	3,020	3,356	3,143
Retained Earnings	39,038	37,164	32,102	28,819	25,928	23,530
Treasury Stock	-1,304	-1,229	-1,092	-398.03	-664.94	-1,495
Comprehensive Income & Other	19.42	16.97	19.32	3.23	-12.16	-4.79
Total Common Equity	46,987	45,520	40,466	37,824	35,003	30,504
Minority Interest	562.71	570.39	567.29	589.35	568.85	282.7
Shareholders' Equity	47,550	46,090	41,033	38,413	35,572	30,787
Total Liabilities & Equity	51,293	50,136	43,785	42,371	39,266	34,730
Total Debt	108.67	110.16	75.18	1,360	151.59	-
Net Cash (Debt)	24,087	24,979	20,770	16,511	18,570	16,433
Net Cash Growth	11.03%	20.27%	25.79%	-11.08%	13.00%	21.15%
Net Cash Per Share	3.84	3.94	3.28	2.58	2.91	2.57
Filing Date Shares Outstanding	6,247	6,362	6,361	6,367	6,382	6,355
Total Common Shares Outstanding	6,247	6,362	6,361	6,367	6,382	6,355
Working Capital	32,607	31,681	28,734	27,295	26,786	24,278
Book Value Per Share	7.52	7.16	6.36	5.94	5.48	4.80
Tangible Book Value	45,606	44,328	39,582	37,304	34,561	30,163
Tangible Book Value Per Share	7.30	6.97	6.22	5.86	5.42	4.75
Buildings	-	3,975	3,854	3,541	2,700	2,141
Machinery	-	6,104	5,969	5,684	5,120	4,063
Construction In Progress	-	1,688	1,101	1,193	1,659	1,305

Updated Oct 24, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.